𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Kinase inhibition: A novel mechanism of neuroprotection in a model of LRRK2 Parkinsonism

✍ Scribed by Stephen G. Reich

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
44 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Leucine-rich repeat kinase 2 (LRRK2): A
Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease
✍ Payal N. Gandhi; Shu G. Chen; Amy L. Wilson-Delfosse 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB

## Abstract Parkinson's disease (PD) is the most common neurodegenerative movement disorder, with a prevalence of more than 1% after the age of 65 years. Mutations in the gene encoding leucine‐rich repeat kinase‐2 (__LRRK2__) have recently been linked to autosomal dominant, late‐onset PD that is cl

A novel LRRK2 mutation in an Austrian co
A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease
✍ Dietrich Haubenberger; Silvia Bonelli; Christoph Hotzy; Petra Leitner; Peter Lic 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Abstract To investigate the frequency of mutations in the Leucine‐Rich Repeat Kinase 2 gene (__LRRK2__) in a sample of Austrian Parkinson's disease (PD) patients, we sequenced the complete coding region in 16 patients with autosomal dominant PD. Furthermore, we sequenced exons 31, 35, and 41 add

Inhibition of the cyclooxygenase isoenzy
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease
✍ Peter Teismann; Boris Ferger 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 2 views

To study the possible role of the isoenzymes of cyclooxygenase COX-1 and COX-2 in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease we used acetylsalicylic acid, a COX-1/COX-2 inhibitor, in comparison with meloxicam, a preferential COX-2 inhibitor. As markers

Neuroprotective effect of riluzole in a
Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence
✍ Maria C. Obinu; Michel Reibaud; Véronique Blanchard; Saliha Moussaoui; Assunta I 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

## Abstract Our study aimed to determine whether riluzole, which has shown efficacy as a disease‐modifying agent in amyotrophic lateral sclerosis (ALS), is neuroprotective in a marmoset model of Parkinson's disease (PD). Reduction of energy demand by riluzole could be a rational neuroprotective str

PHNO, a novel dopamine agonist, in anima
PHNO, a novel dopamine agonist, in animal models of parkinsonism
✍ Dr. William Koller; Gregory Herbster; John Gordon 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB

PHNO, a naphthoxazine compound, was investigated in animal models of central dopaminergic activity. The drug in doses of 5-300 micrograms/kg when administered subcutaneously, or transdermally, induced stereotypic behavior in rats which was blocked by haloperidol but not by reserpine pretreatment. In

Lack of G2019S LRRK2 mutation in a cohor
Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease
✍ Hon-Chung Fung; Chiung-Mei Chen; John Hardy; Dena Hernandez; Andrew Singleton; Y 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

## Abstract Mutations in the leucine‐rich repeat kinase 2 (__LRRK2__) gene have been shown to cause autosomal dominant and sporadic Parkinson's disease (PD). We report here the frequency of a common heterozygous mutation, 2877510G>A, which produces a glycine‐to‐serine amino acid substitution at cod